Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Tejal Amar Patel M.D.

Tejal Amar Patel, M.D.

Assistant Member 
Cancer Research Program
Houston Methodist Research Institute

E-mail: tapatel@houstonmethodist.org
Phone: 713-441-9948


B.S.   The University of Texas at Dallas (Biology)
M.D.   The University of Texas Medical Branch at Galveston (UTMB)

Postdoctoral Training

Internship, Internal Medicine, Mayo Graduate School of Medicine, Jacksonville, Florida
Residency, Internal Medicine, Mayo Graduate School of Medicine, Jacksonville, Florida
Fellowship, Hematology and Oncology, Mayo Graduate School of Medicine, Jacksonville, Florida



Dr. Patel earned her medical degree from the University of Texas Medical Branch at Galveston in 2003. She completed residency and fellowship training at Mayo Graduate School of Medicine in Jacksonville, Florida.  She held a faculty appointment at the Mayo Graduate School of Medicine before joining the Methodist Cancer Center in 2012 as director of the high risk clinic.  As a member of the HMRI Cancer Research Program, she directs research focusing on breast cancer and breast cancer prevention.  Dr. Patel has published several articles in peer reviewed journals.  

Description of Research

Dr. Patel’s research program focuses on identifying and treating patients at high risk of breast cancer.  Current research efforts aim to address the limitations of treatments currently available for prevention.  Dr. Patel and her research team are developing clinical trials for compounds with less toxicity that can provide better compliance.  She is also collaborating with her scientific partners to explore new ways of delivering currently approved treatments for breast cancer.

Major Areas of Research

Breast cancer, breast cancer prevention

Recent Publications

Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr;138(2):427-35. PubMed PMID: 23479422

Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer. 2010 Jun;10(3):196-208. PMID: 20497918

Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA. Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist. 2010;15(5):466-75. PMID: 20427382

Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010 Jun;121(2):261-71. PMID: 20229176

Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol. 2010 Feb;21(2):269-74. PMID: 19901014